Updates are available Correction dated 2021-04-06
Click to view Correction: https://doi.org/10.1186/s13075-021-02490-2
-
Authors
Mirizio, Emily
Tabib, Tracy
Wang, Xinjun
Chen, Wei
Liu, Christopher
Lafyatis, Robert
Jacobe, Heidi
Torok, Kathryn S. http://orcid.org/0000-0002-1662-143X
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR075761, 5U 01 AI 1250505)
Scleroderma Foundation (Established Investigator Award, The Stephen J Katz, MD Memorial Grant)
Nancy Taylor Foundation for Chronic Diseases
- License Information
-
More Information
Article History
Received: 31 July 2020
Accepted: 4 October 2020
First Online: 9 November 2020
Change Date: 6 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13075-021-02490-2
Ethics approval and consent to participate
: Biological samples were collected under informed consent through the Morphea in Adults and Children (MAC) Cohort, an institutional review board-approved registry that was established at the University of Texas Southwestern Medical Center (UTSWMC) in 2007 designed to better understand the demographic characteristics, clinical outcomes, and autoimmune features of those with morphea (localized scleroderma). The study was approved by the UTSWMC institutional review board (IRB) (CR 00017717/ STU 112010-028), and patients were enrolled with IRB-approved informed consent and Health Insurance Portability and Accountability Act forms. Material Transfer Act (MTA) MTA00004124 and Data Use Agreements (DUA) DUA00000737AM1 were established between the University of UTSW and University of Pittsburgh to transfer samples and associated clinical data for analyses.
: Not applicable
: The authors declare that they have no competing interests.
